Weronika Zofia Świtlik1,2, Anna Bielecka-Kowalska3, Michał Seweryn Karbownik4, Radzisław Kordek5, Maciej Jabłkowski6, Janusz Szemraj1,7. 1. Department of Medical Biochemistry, Medical University of Lodz, Mazowiecka Street 6/8 92-215 Lodz, Poland. 2. Department of Biochemistry, Faculty of Agriculture & Biology, Warsaw University of Life Sciences - SGGW, Nowoursynowska Street 159, 02-776 Warsaw, Poland. 3. Non-public Medical Center 'Akoria', Rydzowa Street 22, 92-157 Lodz, Poland. 4. Department of Pharmacology & Toxicology, Medical University of Lodz, Zeligowskiego Street 7/9, 90-752 Lodz, Poland. 5. Department of Pathology Chair of Oncology, Medical University of Lodz, Pomorska Street 251, 92-213 Lodz, Poland. 6. Department of Infectious & Liver Diseases, Medical University of Lodz, Kniaziewicza Street 1/5, 91-347 Lodz, Poland. 7. BioNanoPark Laboratories, Lodz Regional Park of Science & Technologies, Dubois Street 114/116, 93-465, Lodz, Poland.
Abstract
Aim: To assess the diagnostic value of selected miRNAs from various material collected from hepatocellular carcinoma (HCC) patients. Patients & methods: Tissue, serum, urine and fecal samples from HCC patients and healthy individuals were screened for associated miRNAs using microarray analysis; the selected miRNAs were then validated by real time-quantitative PCR on 65 patients. Results: Serum miR-122, a combination of serum miR-155 with miR-885-5p, a combination of urinary miR-532-3p with miR-765, and fecal miR-320a displayed 100% efficiency in discriminating patients from controls. A combination of urinary miR-532-3p and miR-765 allowed patients with neoplastic grade G3 to be distinguished from those with G1 and G2. Conclusion: Additionally to serum, urine and feces also appeared to be valuable source of potential HCC noninvasive miRNA biomarkers.
Aim: To assess the diagnostic value of selected miRNAs from various material collected from hepatocellular carcinoma (HCC) patients. Patients & methods: Tissue, serum, urine and fecal samples from HCC patients and healthy individuals were screened for associated miRNAs using microarray analysis; the selected miRNAs were then validated by real time-quantitative PCR on 65 patients. Results: Serum miR-122, a combination of serum miR-155 with miR-885-5p, a combination of urinary miR-532-3p with miR-765, and fecal miR-320a displayed 100% efficiency in discriminating patients from controls. A combination of urinary miR-532-3p and miR-765 allowed patients with neoplastic grade G3 to be distinguished from those with G1 and G2. Conclusion: Additionally to serum, urine and feces also appeared to be valuable source of potential HCC noninvasive miRNA biomarkers.